<DOC>
	<DOCNO>NCT02742441</DOCNO>
	<brief_summary>This Phase 3 study ( Study 310 ) design determine compare efficacy safety 122-0551 Foam Vehicle Foam apply twice daily two week subject plaque psoriasis .</brief_summary>
	<brief_title>A Comparison 122-0551 Foam Versus Vehicle Foam Subjects With Plaque Psoriasis ( Study 310 )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Subject male nonpregnant female least 18 year age time Screening Visit . 2 . Subject provide write informed consent . 3 . Subject willing able apply test article ( ) direct , comply study instruction commit followup visit duration study . 4 . Subject clinical diagnosis stable plaque psoriasis involve minimum 2 % 12 % body surface area ( BSA ) ( exclude face , scalp , groin , axillae intertriginous area ) . 5 . Subject Investigator 's Global Assessment ( IGA ) score least three ( 3 = moderate ) Baseline Visit . 6 . Females must postmenopausal , surgically sterile use effective method birth control , negative urine pregnancy test ( UPT ) Baseline Visit . 1 . Subject spontaneously improve rapidly deteriorate plaque psoriasis . 2 . Subject guttate , pustular , erythrodermic nonplaque form psoriasis . 3 . Subject physical condition , investigator 's opinion , might impair evaluation plaque psoriasis , expose subject unacceptable risk study participation . 4 . Subject use phototherapy ( include laser ) , photochemotherapy form photo base therapy treatment psoriasis within 30 day prior Baseline Visit . 5 . Subject use systemic methotrexate , retinoids , systemic corticosteroid [ include intralesional , intraarticular , intramuscular corticosteroid ] , cyclosporine analogous product within 90 day prior Baseline Visit . 6 . Subject use systemic biologic therapy ( i.e. , FDAapproved experimental therapy ) within five ( 5 ) halflives biologic prior Baseline Visit . Published documented halflife product provide commercial supplier Sponsor use establish value . 7 . Subject prolonged exposure natural artificial source ultraviolet radiation within 30 day prior Baseline Visit intending exposure study opinion investigator think modify subject 's disease . 8 . Subject use topical body ( exclude scalp ) psoriasis therapy ( include coal tar , anthralin , steroid , retinoids vitamin D analog ) within 14 day prior Baseline Visit . 9 . Subject use emollients/moisturizers area treat within four hour prior clinical evaluation Baseline Visit . 10 . Subject currently use lithium Plaquenil ( hydroxychloroquine ) . 11 . Subject currently use betablocking medication ( e.g. , propranolol ) angiotensin convert enzyme ( ACE ) inhibitor dose stabilize , opinion investigator . 12 . Subject history sensitivity ingredient test article . 13 . Subject pregnant , lactating , plan become pregnant study . 14 . Subject currently enrol investigational drug device study . 15 . Subject use investigational drug investigational device treatment within 30 day prior Baseline Visit . 16 . Subject previously enrol study treat test article . 17 . Subject know noncompliant unlikely comply requirement study protocol ( e.g. , due alcoholism , drug dependency , mental incapacity ) opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>